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of cognitive and affective impairment, as in patients not re- 
ceiving radiotherapy. This theory, however, is not supported 
by the fact that the interval from diagnosis to testing in our 
study ranged from 1 year to more than 12 years without 
finding an influence of the length of the interval on neuropsy- 
chological function. This not only holds true for all patients 
studied, but also for the radiotherapy group. 
Although we agree with Kreth and colleagues that a pro- 
spective clinical trial on this issue, with longitudinal cognitive 
and affective testing, is clearly to be preferred, this does not 
alter the fact that the main conclusion of our study remains 
well substantiated. 
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by the Dutch Guillain-Barre Study Group [l], is now ethical 
and its interpretation will be less complicated. Like the Dutch 
investigators, we had also expected GBS to respond to ste- 
roids because the underlying pathological process is usually 
inflammatory and GBS forms part of a spectrum of condi- 
tions including chronic inflammatory demyelinating polyra- 
diculoneuropathy, which does respond to steroids. Neverthe- 
less, neither of the published controlled trials of steroids in 
GBS support their use [2,  41. The provocative observations 
of the Dutch Guillain-Barr6 Study Group make a possible 
beneficial interaction between W I G  and IVMP worth ex- 
ploring; but, until a more conclusive trial has been published, 
we do not recommend the use of steroids in GBS in practice. 
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The Dutch Guillain-Barre Study Group [l} treated 25 pa- 
tients with Guillain-Barre syndrome (GBS) with intravenous 
methylprednisolone (IVMP) and found that their functional 
improvement after 4 weeks was greater than that of 74 histor- 
ical controls. We had previously published the results of a 
double-blind controlled trial of IVMP in 242 GBS patients 
121 in which there was no difference in outcome between 
the patients treated with IVMP and those not so treated. The 
authors of the Dutch Study maintain that our trial was not 
conclusive, drawing attention to our own comments on the 
possible interference of plasma exchange (PE) with the out- 
come. In our trial the ethical imperative to permit the use of a 
procedure of proven and, at the time, unrivaled effectiveness, 
resulted in slightly more patients in the placebo group (77/ 
118) than in the IVMP group receiving PE (66/124). In antic- 
ipation of this problem the randomizing neurologist was re- 
quired to declare whether patients were to receive PE (63 
placebo, 61 IVMP), not receive PE (27 placebo, 22 IVMP), 
or possibly receive PE (28 placebo, 4 1 IVMP). Allowing for 
age and sex differences, we studied the effects of IVMP in 
each of these groups separately and failed to detect either a 
significant beneficial or adverse effect in terms of grade 
change 4 weeks from randomization, or proportion improv- 
ing by one or more grades after 4 weeks, or time to recovery 
of unaided walking. 
Following publication of the Dutch trial of IVIG in GBS 
[3}, a controlled trial of IVMP added to IVIG, as proposed 
Controlled trial of prednisolone in acute polyneuropathy. Lancet 
1978;2:750-753 
Reply 
L. H. Visser and F. G. A. van der Meche 
We thank D r  R. Hughes and D r  A. Swan for the additional 
information regarding their double-blind controlled trial of 
intravenous methylprednisolone (MP) in 242 patients with 
Guillain-Barre syndrome (GBS). Subgroup analysis did not 
reveal any significant beneficial effect of MP. Although we 
compared patients treated with MP with historical controls, 
we emphasize that both groups, the 25 patients of the pilot 
study as well as the 74 historical controls, were treated with 
intravenous immune globulins (IgIV) [ l ,  2). We believe that 
available data support the conclusion that MP alone has little 
or no effect, but that MP in combination with IgIV (MP- 
IgIV) may give a synergistic response El). Actually, MP 
seems to have its effect during the first 2 weeks after start 
of therapy. Thirteen ( 5 2 % )  of the 25 patients treated with 
MP-IgIV showed an improvement in functional score in 
comparison with 20 (27%) of the 74 patients treated with 
IgIV (Table). 
A multicenter double-blind study in which GBS patients 
are randomly assigned to either IgIV and placebo or to IgIV 
with M P  has been designed and this trial started in August 
1994. We fully agree with the recommendation of Drs 
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EHect of Treatment in Guillain-Bawi Syndrome Patients 
During the First Two Wee& after Start of lglV or MP-IgIV, 
Measured with a Seven-Point Functional Scale" 
Difference in Functional IgIV MP-IgIV 
Score in the First Two Weeks (n = 25) 
A Improvement 20 (27%) 13 (52%) 
B Stable 37 (50%) 8 (32%) 
C Deterioration 17 (23%) 4 (16%) 
(n = 74) 
'Functional score: 0 denotes healthy; 1,  having minor symptoms and 
signs but fully capable of manual word; 2,  able to walk 210 m 
without assistance; 3 ,  able to walk 210 m with a walker or support; 
4, bedridden or chairbound; 5, requiring assisted ventilation for at 
least part of the day; and 6 ,  dead. 
IgIV = intravenous immune globulins; MP = methylprednisolone. 
Hughes and Swan not to use steroids in GBS until the results 
of our pilot study have been confirmed by this double-blind 
trial. 
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4-Aminopyridine in the 
Symptomatic Treatment of 
Multiple Sclerosis 
Floyd A. Davis, MD, Dusan Stefoski, MD, 
and Fred N. Quandt, PhD 
4-Aminopyridine (4-AP) is believed to improve symptoms 
in multiple sclerosis (MS) by blocking internodal K channels 
and restoring conduction in blocked demyelinated axons. 
Like improvements in MS with body cooling, the effect is 
due to a prolongation of the action potential [I]. Recently, 
a letter submitted by Drs Felts and Smith [2} suggests that 
the action of 4-AP is at central synapses, to promote transmit- 
ter release, rather than at the site of demyelination. Although 
the letter was prompted by a report showing the lack of 
action of 3,4-diaminopyridine (3,4-DAP) in patients with de- 
myelinating peripheral neuropathies 131, it has now been re- 
ported that higher doses of 3,4-DAP can reverse block in 
some of these conditions E47. 
The main observation raised in their letter to support the 
alternative hypothesis is their finding that the minimum con- 
centration of 4-AP required to reverse block in experimental 
demyelination is 100 (*M, while the effective concentration 
of 4-AP estimated for effects in MS patients is much lower. 
The actual concentration in cerebrospinal fluid is difficult to 
estimate but may be higher than the value of 5 FM estimated 
by Felts and Smith {Z). 
However, it should be noted that the action of 4-AP to 
block K channels is now known to be at the cytoplasmic 
surface of the channel. 4-AP can block K channels recorded 
from a patch of membrane in an intact neuron when it is 
applied to the bath, but it must first cross the membrane to 
reach the 4-AP binding site { S ,  61. In addition, the sensitivity 
of K channels to 4-AP is much greater when applied directly 
to the cytoplasmic surface of the channel using inside-out 
patch clamped membranes than when applied to the external 
surface IS}. For 4-AP-sensitive K channels in mouse neuro- 
blastoma cells, 25 JLM 4-AP produces a greater effect when 
applied internally than does 500 (*M 4-AP applied externally, 
a 20-fold difference in concentration IS}. Given these obser- 
vations, it is probable that low concentrations of 4-AP outside 
accumulate inside a neuron over time and block at an internal 
site having high affinity. The effective concentrations in ex- 
periments in which 4-AP is applied over a short time may 
therefore not reflect the lower concentrations required in 
vivo. Accordingly, we feel that the hypothesis that 4-AP acts 
to promote conduction by block of axonal K channels cannot 
be ruled out by the argument cited by Felts and Smith [2f. 
The pharmacologic actions of 4-AP may well include an en- 
hancement of transmitter release. However, the important 
issue is not whether the enhancement is more sensitive to 
4-AP than block of axonal K channels. The question that 
needs to be resolved is whether an increase in synaptic activ- 
ity can contribute to the mechanism by which 4-AP causes 
an improvement of signs in MS. 
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